Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing- remitting multiple sclerosis

Annals of Neurology

Volumn 46, Issue 2, 1999, Pages 197-206

  Li, David K B ^a   Paty, Donald W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; PLACEBO; RECOMBINANT BETA INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PROGNOSIS; RECURRENCE;

EID: 0032864616     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P     Document Type: Article

References (24)

1. Kastrukoff LF, Oger JJ, Hashimoto SA, et al. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990;40:479-486
2. Paty DW, Li DKB, the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
3. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
4. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-413
5. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258
6. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294
7. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991; 54:683-688
8. Stewart WA, Hall LD, Berry K, et al. Magnetic resonance imaging in multiple sclerosis: pathological correlation studies in 8 cases. Neurology 1986;36(Suppl 1):320
9. Paty DW, Moore GRW. Magnetic resonance imaging changes as living pathology in multiple sclerosis. In: Paty DW, Ebers GC, ed. Multiple sclerosis. Philadelphia: FA Davis, 1997: 328-369
10. The PRISMS Study Group. Randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis: clinical results. Lancet 1998;352: 1498-1504
11. Sandberg-Wollheim M, Hommes OR, Hughes RAC, et al. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis 1995;1(Suppl):S48-S50
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: 1444-1452
13. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45:1808-1814
14. Koopmans RA, Li DKB, Redekop WK, et al. The use of magnetic resonance imaging in monitoring interferon therapy of multiple sclerosis. J Neuroimaging 1993;3:163-168
15. Zhao GJ, Li DKB, Wolinsky JS, et al. Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. J Neuroimaging 1997;7:1-7
16. Sipe JC, Romine JS, Koziol JA, et al. Cladibrine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13
17. Simon JH, Scherzinger A, Raff U, Li X. Computerized method of lesion volume quantitation in multiple sclerosis: error of serial studies. AJNR 1997;18:580-582
18. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon-β-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87
19. van Walderveen MAA, Barkhof F, Hommes OR, et al. Correlating MRI in clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/TE (T1 weighted) images. Neurology 1995;45:1684-1690
20. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multiarray coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632-2637
21. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-67
22. Mackay A, Whittall K. Adler J, et al. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med 1994;31:673-677
23. Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76-82
24. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44: 635-641